Media headlines about Bioamber (NYSE:BIOA) have trended somewhat positive on Sunday, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Bioamber earned a news sentiment score of 0.11 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.9292892152076 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
Bioamber (BIOA) opened at $0.43 on Friday. Bioamber has a twelve month low of $0.32 and a twelve month high of $5.93. The company has a debt-to-equity ratio of 0.24, a quick ratio of 0.75 and a current ratio of 1.08.
Several research analysts have recently issued reports on the company. Cowen reaffirmed a “hold” rating and issued a $1.00 price objective on shares of Bioamber in a research note on Friday, November 10th. ValuEngine cut Bioamber from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Bioamber in a report on Wednesday, November 8th. Finally, Zacks Investment Research upgraded Bioamber from a “sell” rating to a “hold” rating in a report on Tuesday, January 9th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company’s stock. Bioamber has an average rating of “Hold” and a consensus price target of $6.50.
WARNING: This piece of content was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/14/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-bioamber-bioa-stock-price.html.
BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.
Receive News & Ratings for Bioamber Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioamber and related companies with MarketBeat.com's FREE daily email newsletter.